Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;51(3):303-312.
doi: 10.1111/hepr.13606. Epub 2021 Feb 22.

Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe carbon ion radiotherapy for hepatocellular carcinoma in caudate lobe

Shohei Okazaki  1   2 , Kei Shibuya  1 , Shintaro Shiba  2 , Masahiko Okamoto  1 , Yuhei Miyasaka  1 , Naoto Osu  1 , Motohiro Kawashima  2 , Satoru Kakizaki  3   4 , Kenichiro Araki  5 , Ken Shirabe  5 , Tatsuya Ohno  1   2
Affiliations

Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe carbon ion radiotherapy for hepatocellular carcinoma in caudate lobe

Shohei Okazaki et al. Hepatol Res. 2021 Mar.

Abstract

Aim: The treatment of hepatocellular carcinoma in the caudate lobe (HCCCL) is technically challenging. We aimed to investigate the efficacy and toxicity of carbon ion radiotherapy (C-ion RT) for HCCCL.

Methods: Patients with HCCCL treated with C-ion RT at our hospital between January 2011 and December 2018 were evaluated. The total dose was 52.8 or 60 Gy (relative biological effectiveness) in four or 12 fractions depending on the distance between the tumor and the gastrointestinal tract. The survival outcome, the presence or absence of recurrence (local recurrence, intrahepatic recurrence outside the irradiation field, or extrahepatic recurrence), and acute/late adverse events were evaluated.

Results: Nine patients were included. The median tumor size was 3.4 cm, and the median follow-up duration was 18.3 months for all patients. No patient developed local recurrence during follow-up. Five patients subsequently developed intrahepatic recurrence outside the irradiation field and two had extrahepatic metastasis. Five patients died of hepatocellular carcinoma. No acute adverse events of grade ≥2 were observed. Two patients experienced grade 2 or 3 late adverse events, including obstructive jaundice, hepatic encephalopathy, ascites, and edema.

Conclusion: Carbon ion radiotherapy for HCCCL achieved excellent local control with acceptable adverse events and can thus be a curative treatment option for HCCCL.

Keywords: carbon ion radiotherapy; caudate lobe; hepatocellularcarcinoma.

PubMed Disclaimer

References

REFERENCES

    1. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683-91.
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Canc. 2015;136:E359-86.
    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301-14.
    1. Liu P, Yang JM, Niu WY, Kan T, Xie F, Li DQ, et al. Prognostic factors in the surgical treatment of caudate lobe hepatocellular carcinoma. World J Gastroenterol. 2010;16:1123-8.
    1. Tanaka S, Shimada M, Shirabe K, Maehara SI, Tsujita E, Taketomi A, et al. Surgical outcome of patients with hepatocellular carcinoma originating in the caudate lobe. Am J Surg. 2005;190:451-5.

LinkOut - more resources